Curis (CRIS)
Curis Revenue Growth: 7658%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CRIS Revenue Growth Rankings
| Overall | 99th percentile | 3 of 4358 |
| Sector | 99th percentile | 2 of 456 in Healthcare |
| Industry | 98th percentile | 2 of 126 in Biotechnology |
CRIS Revenue Growth Range, Past 5 Years
| Minimum | -98.94% | Mar 2011 |
| Maximum | 13947% | Dec 2011 |
| Average | 1144% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these CRIS related companies
CRIS News
Curis Announces Collaborators' Presentation of Erivedge(TM) and Debio 0932 Clinical Data at ASCO Annual Meeting
May 17, 7:00AM GlobeNewswire
May 17, 7:00AM GlobeNewswire
Listen to $CRIS Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3iVS
about 20 days ago by earningscast
about 20 days ago by earningscast
Listen to $CRIS Curis, Inc. at Deutsche Bank AG Health Care Conference - live at 10:00 AM, ondemand after - http://stks.co/3hQ9
about 21 days ago by earningscast
about 21 days ago by earningscast
Curis (CRIS) Says Roche Submitted Erivedge for Registration in Australia, Receives $4M Milestone Payment
May 07, 7:19AM Street Insider
May 07, 7:19AM Street Insider
Curis to Release First Quarter 2012 Financial Results and Hold Conference Call on May 8, 2012
May 01, 7:00AM GlobeNewswire
May 01, 7:00AM GlobeNewswire
Curis to Present at the Deutsche Bank Securities 37th Annual Health Care Conference
Apr 30, 7:00AM GlobeNewswire
Apr 30, 7:00AM GlobeNewswire
$CRIS http://stks.co/3ZBm Breaks out over 5.10, 5.2 and 5.6 first stops
about 30 days ago by harmongreg
about 30 days ago by harmongreg
Listen to $CRIS Curis, Inc. at BioCentury & Thomson Reuters Future Leaders in th - live at 02:00 PM, ondemand after - http://stks.co/3RHc
about 38 days ago by earningscast
about 38 days ago by earningscast
$CRIS filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3LOn
about 45 days ago by MarketBrief
about 45 days ago by MarketBrief
Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference
Apr 13, 7:00AM GlobeNewswire
Apr 13, 7:00AM GlobeNewswire
Curis Presents Data on PI3K and HDAC Inhibitor CUDC-907 at AACR Annual Meeting 2012
Apr 04, 9:03AM GlobeNewswire
Apr 04, 9:03AM GlobeNewswire
Curis to Present at the 32nd Annual Cowen and Company Health Care Conference
Feb 27, 7:00AM GlobeNewswire
Feb 27, 7:00AM GlobeNewswire
Curis to Present at the 2012 RBC Capital Markets' Healthcare Conference
Feb 21, 7:00AM GlobeNewswire
Feb 21, 7:00AM GlobeNewswire
Curis and Debiopharm Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
Feb 16, 7:00AM GlobeNewswire
Feb 16, 7:00AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CRIS | 4.60 | -0.06 | -1.29% | 356.55M |
| CRIC | 5.60 | +0.00 | +0.00% | 793.91M |
| CRI | 54.64 | +1.67 | +3.15% | 3.217B |
| CRF | 6.181 | +0.10 | +1.67% | |
| CRESY | 7.79 | +0.19 | +2.50% | 390.75M |
| CREG | 1.11 | +0.00 | +0.00% | 48.32M |
| CREE | 26.11 | +0.20 | +0.77% | 3.031B |
| CPLP | 7.54 | +0.03 | +0.40% | 523.05M |
| CPLA | 31.27 | +0.64 | +2.09% | 425.58M |
| CPL | 23.94 | +0.17 | +0.72% | 11.52B |
